The stock of Ophthotech Corp (NASDAQ:OPHT) gapped down by $5.63 today and has $41.98 target or 9.00% below today’s $46.13 share price. The 8 months technical chart setup indicates high risk for the $1.55B company. The gap down was reported on Oct, 1 by Barchart.com. If the $41.98 price target is reached, the company will be worth $139.50M less.
Gaps down are helpful for identifying a resistance level and to could also be used as a tradeable event. If traders are short the stock and it experiece gap down, then its usually advisable to hold the short for a bigger down move. Back-tests of such patterns show that two-thirds of the these patterns the stock performance worsens after the gap. The area gaps close 91% of the time, the breakaway gaps 1%, the continuation gaps 9% and the exhaustion gaps 64%. The stock decreased 14.76% or $7.99 during the last trading session, hitting $46.13. About 5.44M shares traded hands or 909.86% up from the average. Ophthotech Corp (NASDAQ:OPHT) has risen 2.42% since February 29, 2016 and is uptrending. It has underperformed by 8.00% the S&P500.
Analysts await Ophthotech Corp (NASDAQ:OPHT) to report earnings on November, 3. They expect $-1.59 EPS, down 39.47% or $0.45 from last year’s $-1.14 per share. After $-0.85 actual EPS reported by Ophthotech Corp for the previous quarter, Wall Street now forecasts 87.06% negative EPS growth.
Ophthotech Corp (NASDAQ:OPHT) Ratings Coverage
Out of 10 analysts covering Ophthotech Corporation (NASDAQ:OPHT), 9 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 90% are positive. Ophthotech Corporation has been the topic of 14 analyst reports since August 4, 2015 according to StockzIntelligence Inc. Suntrust Robinson initiated it with “Buy” rating and $100 target price in Friday, January 8 report. Goldman Sachs downgraded it to “Sell” rating and $45 target price in Friday, August 7 report. The rating was initiated by Citigroup on Thursday, September 3 with “Buy”. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, August 6. Citigroup maintained Ophthotech Corp (NASDAQ:OPHT) on Thursday, August 4 with “Buy” rating. As per Tuesday, August 4, the company rating was maintained by Chardan Capital Markets. The firm has “Overweight” rating given on Wednesday, April 27 by Barclays Capital. The stock has “Buy” rating given by Chardan Capital Markets on Monday, December 14. The rating was initiated by SunTrust with “Buy” on Thursday, January 7. The company was upgraded on Thursday, June 2 by JP Morgan.
According to Zacks Investment Research, “Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1.95 in Q2 2016. Its up 0.45, from 1.5 in 2016Q1. The ratio is positive, as 21 funds sold all Ophthotech Corp shares owned while 34 reduced positions. 38 funds bought stakes while 69 increased positions. They now own 41.31 million shares or 29.52% more from 31.90 million shares in 2016Q1.
Moreover, Mufg Americas Corp has 0% invested in Ophthotech Corp (NASDAQ:OPHT) for 203 shares. Moreover, Putnam Invs Ltd Liability Company has 0.01% invested in Ophthotech Corp (NASDAQ:OPHT) for 62,627 shares. Silvercrest Asset Gp Ltd last reported 12,000 shares in the company. Principal Gp holds 0% of its portfolio in Ophthotech Corp (NASDAQ:OPHT) for 5,366 shares. Nationwide Fund Advsrs owns 64,148 shares or 0.01% of their US portfolio. Estabrook Cap Management owns 325 shares or 0% of their US portfolio. Pura Vida Lc has 1.14% invested in the company for 52,500 shares. Moreover, Dekabank Deutsche Girozentrale has 0.03% invested in Ophthotech Corp (NASDAQ:OPHT) for 56,150 shares. Manufacturers Life Insur The accumulated 0% or 20,917 shares. Allianz Asset Mngmt Ag last reported 0.01% of its portfolio in the stock. State Board Of Administration Of Florida Retirement Systems has invested 0% of its portfolio in Ophthotech Corp (NASDAQ:OPHT). Prudential Finance holds 0% of its portfolio in Ophthotech Corp (NASDAQ:OPHT) for 5,587 shares. Moreover, Polar Capital Ltd Liability Partnership has 0.04% invested in Ophthotech Corp (NASDAQ:OPHT) for 43,076 shares. Endurance Wealth Inc last reported 1,500 shares in the company. State Of New Jersey Common Pension Fund D owns 17,500 shares or 0% of their US portfolio.
Insider Transactions: Since April 1, 2016, the stock had 1 buying transaction, and 12 selling transactions for $76.70 million net activity. 20,000 shares with value of $935,875 were sold by PATEL SAMIR CHANDRAKANT on Friday, April 29. $1.58M worth of Ophthotech Corp (NASDAQ:OPHT) was sold by GUYER DAVID R on Wednesday, June 1. Novo A/S had sold 1.30M shares worth $63.70 million. The insider Bolte Axel bought $199,395. On Wednesday, June 1 SBLENDORIO GLENN sold $38,381 worth of the stock or 671 shares.
More notable recent Ophthotech Corp (NASDAQ:OPHT) news were published by: Fool.com which released: “Here’s Why Ophthotech Corporation Is Dropping Today” on September 30, 2016, also Fool.com with their article: “Why Ophthotech Corp. Shares Soared 14.9% in May” published on June 09, 2016, Fool.com published: “Why Ophthotech Corp. Plunged 42% in March” on April 07, 2016. More interesting news about Ophthotech Corp (NASDAQ:OPHT) were released by: Fool.com and their article: “Why Ophthotech Corporation Shares Tumbled 31% in January” published on February 06, 2016 as well as Fool.com‘s news article titled: “Why Ophthotech Corporation Shares Soared Higher Last Month” with publication date: December 04, 2015.
OPHT Company Profile
Ophthotech Corporation, incorporated on January 5, 2007, is a biopharmaceutical company. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV), a specific type of wet AMD. It is also investigating the potential of an ophthalmic formulation for tivozanib, a molecule VEGF tyrosine kinase inhibitor, for which the Company has an option for a license.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.